Company Profile
CervoMed Stock Price, News & Catalysts
- Ticker:
- CRVO
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
2.62 USD (+2.34%)
Close
Last updated: August 21, 2026
27.8M USD
Market cap
Why the stock is moving
As of Aug 21, 2026, CRVO closed up 2.34% at $2.62. No new same-company headline was identified in the current news window.
Company overview
Neuroinflammation and Synaptic Dysfunction
CervoMed develops treatments for age-related brain disorders by targeting mechanisms that impair neuronal signaling. Its lead candidate focuses on p38 alpha MAP kinase, a driver of neuroinflammation and synaptic dysfunction.
Neflamapimod
Neflamapimod is an oral, brain-penetrant small molecule that selectively inhibits p38 alpha. It is intended to restore synaptic function and improve neuronal health in disorders affecting cholinergic brain networks.
Dementia With Lewy Bodies
The Phase 2b RewinD-LB study generated supportive results in dementia with Lewy bodies. CervoMed has selected the Phase 3 formulation and dose and aligned with U.S. and other regulators on a global, approximately 300-patient confirmatory trial.
Additional Neurologic Indications
Phase 2a studies evaluate neflamapimod in recovery after ischemic stroke and non-fluent-variant primary progressive aphasia. The molecule has also been selected for the EXPERTS-ALS platform trial.
Future catalysts
- Initiation of the Phase 3 dementia-with-Lewy-bodies trial expected in the second half of 2026, subject to financing.
- Topline Phase 2a ischemic-stroke-recovery data expected in the second half of 2026.
- Initial topline Phase 2a primary-progressive-aphasia data expected in the second half of 2026.
- Initiation of the EXPERTS-ALS trial expected in the second half of 2026.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of CervoMed (CRVO)?
CervoMed (CRVO) most recently closed at 2.62 USD, a +2.34% move versus the previous session.
What is the market cap of CervoMed (CRVO)?
CervoMed currently has a market capitalization of 27.8M USD on BioPharmSignal.
What does CervoMed do?
Neuroinflammation and Synaptic Dysfunction CervoMed develops treatments for age-related brain disorders by targeting mechanisms that impair neuronal signaling. Its lead candidate focuses on p38 alpha MAP kinase, a driver of neuroinflammation and synaptic dysfunction. Neflamapimod Neflamapimod is an oral, brain-penetrant small molecule that selectively...
On which exchange is CRVO stock listed?
CervoMed (CRVO) is associated with NASDAQ, United States, Biopharma.
What is EXPERTS-ALS?
Initiation of the EXPERTS-ALS trial expected in the second half of 2026.
Which conditions is CervoMed targeting with EXPERTS-ALS?
CervoMed is associated with inflammatory disease based on its company overview and current catalyst commentary.
How does CervoMed describe recent progress with EXPERTS-ALS?
Initiation of the EXPERTS-ALS trial expected in the second half of 2026.
What is Neuroinflammation?
Neuroinflammation and Synaptic Dysfunction CervoMed develops treatments for age-related brain disorders by targeting mechanisms that impair neuronal signaling.